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Background: With increasing biobanking of biological samples, methods for large scale extraction of nucleic acids
are in demand. The lack of such techniques designed for extraction from tissues results in a bottleneck in
downstream genetic analyses, particularly in the field of cancer research. We have developed an automated
procedure for tissue homogenization and extraction of DNA and RNA into separate fractions from the same frozen
tissue specimen. A purpose developed magnetic bead based technology to serially extract both DNA and RNA
from tissues was automated on a Tecan Freedom Evo robotic workstation.
Results: 864 fresh-frozen human normal and tumor tissue samples from breast and colon were serially extracted in
batches of 96 samples. Yields and quality of DNA and RNA were determined. The DNA was evaluated in several
downstream analyses, and the stability of RNA was determined after 9 months of storage. The extracted DNA
performed consistently well in processes including PCR-based STR analysis, HaloPlex selection and deep sequencing
on an Illumina platform, and gene copy number analysis using microarrays. The RNA has performed well in RT-PCR
analyses and maintains integrity upon storage.
Conclusions: The technology described here enables the processing of many tissue samples simultaneously with a
high quality product and a time and cost reduction for the user. This reduces the sample preparation bottleneck in
cancer research. The open automation format also enables integration with upstream and downstream devices for
automated sample quantitation or storage.
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Efficient methods for biomolecule extractions from many
tissue samples simultaneously are key components of the
future workflow in molecular profiling of tumors, in
particular in cancer biobanking, research and diagnostics.
A major limitation of current automated procedures is
that they are not developed and validated for the extrac-
tion of nucleic acids from tissue samples. Tissue samples
differ from blood samples in that they are heterogeneous
and may vary in composition from samples with high fat
content and low cell number, such as normal breast, to
very fibrous samples such as muscle and cell dense sam-
ples like spleen. It has therefore not been common prac-
tice to use a universal extraction process for all tissue
types; different tissue types have often been processed
manually with different extraction kits or with titrated* Correspondence: tobias.sjoblom@igp.uu.se
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reproduction in any medium, provided the orinput amounts, which is expensive and time consuming
[1]. The quality of biomolecules extracted from tissues is
variable, and depends on many factors, including time
from removal from the patient to freezing or fixation, sec-
tioning methods employed by the pathology department
and storage following sectioning [2,3]. When possible, it is
preferable to use fresh frozen tissues for extracting RNA
of high integrity and long strands of genomic DNA [4].
Here, we develop and validate an automated extraction
process using magnetic silica bead technology suitable
for the serial extraction of DNA and RNA from many
different types of solid tissues using a minimal number
of reagents [5]. This process was designed to use fresh
frozen tissue as starting material to obtain the highest
quality DNA and RNA for downstream genomic and
transcriptomic analyses, and therefore extracts both DNA
and RNA from the same cells of the same tumor tissue [6].
To demonstrate performance and scalability, we processed
864 solid tissue specimens and assessed the extractedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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PCR-based STR analysis, deep sequencing on an Illumina
platform following a HaloPlex selection, and gene copy
number studies using microarrays.
Methods
Tissue collection and preparation
864 tumor-normal paired colorectal and breast frozen
tissue samples (288 colorectal, 576 breast) as well as 30
samples of liver, prostate, tonsil, colon, breast, thymus,
kidney, skin, uterus and lung were obtained from the
frozen tissue collection at the Department of Pathology,
Academic Hospital Uppsala. This study was approved by
the Regional Ethical Review Board of Uppsala (2007/116)
and written consent was obtained from participants. The
tissues were embedded in OCT and stored at −80°C to
maintain biomolecular integrity [1]. The breast and colon
tumor sections contained a minimum of 50% and 40%
tumor cells, respectively. The blocks were sectioned and
2 or 3 10 μm sections per specimen were collected in
2D barcoded tubes in tube racks of 96 (Micronic
Roborack-96, art. no. MPW51016BC3).
Automated serial extraction of nucleic acids
We recently described a novel process for serial DNA
and RNA extraction employing silica beads with differ-
ential nucleic acid binding affinities [5]. This extraction
procedure was automated on a liquid handling worksta-
tion (Tecan Evo 150 MCA LiHa RoMa) equipped with
wash stations for 96 and 8 tips, respectively, a twin-
block heater with two different constant temperatures
(EchoTherm IC22, Torrey Pines Scientific), and readers
for 1D plate barcodes (Symbol MS954) and 2D tube
barcodes (Ziath), respectively. Briefly, nine 96-well plates
of approximately 25 mg fresh frozen tissue from 864
patient-matched tumor and normal tissues (288 colo-
rectal, 576 breast) were collected as described. Unless
otherwise stated, all liquid transfers were performed
with a 200 μL fixed tip block (Tecan). At the start of
each run, all reagents along with one SBS format tube
rack with 96 samples were loaded on the robotic work-
station and uncapped. The lysis buffer was dispensed
using an 8-channel LiHa pipetting head. After addition
of chaotropic lysis buffer, the samples were incubated
for 15 min at 58°C, followed by incubation with DNA
binding beads for 15 min. All liquid handling after the
initial dispensing of lysis buffer to the tissue samples
was performed using a 96-tip MCA pipetting head with
tip washes between each process step.
The DNA binding beads were captured using a mag-
netic plate (V&P Scientific) and the supernatant trans-
ferred into a new vessel for RNA capture. Meanwhile,
the DNA selective beads were washed three times in
wash buffer and bound DNA eluted in TE buffer. After15 min binding, the RNA binding beads were retrieved
using a magnetic plate and washed first in DNase
(ThermoScientific) containing wash buffer and thereafter
washed and eluted in the same buffer composition as
used for the DNA extraction [5]. The final DNA and RNA
products were transferred to a 96 well Roborack barcoded
storage plate (Micronic, Article No MPW51016BC3). The
worktable layout is shown in Additional file 1: Figure S1.
Quality control of extracted DNA and RNA
The DNA yields from the tissue samples were assessed
by measurements using a High Sensitivity dsDNA kit on
a Qubit® instrument (Invitrogen). The purity of the DNA
was assessed by spectrophotometry (OD 260:280 ratio)
using a Nanodrop instrument (Thermo Scientific). The
integrity of DNA was assessed by separation in a 0.7%
agarose gel (Sigma Aldrich) and staining with SYBR Safe
(Invitrogen). The integrity of selected RNA samples was
assessed using an RNA 6000 Pico Assay on an Agilent
2100 Bioanalyzer instrument (Agilent). The samples were
diluted 1:10 or 1:20 in RNase free water and denatured for
2 min at 70°C before separation. The 28S/18S ribosomal
RNA ratio and RNA integrity (RIN) scores were com-
puted using the Agilent Technologies 2100 Expert soft-
ware package.
Performance evaluation in genomic analyses
The extracted DNA was used in several downstream
applications including PCR-based STR analysis, deep
sequencing on an Illumina platform following a HaloPlex
selection (Agilent), Sanger sequencing and gene copy
number analyses.
PCR-based STR analysis was performed on 238 colo-
rectal DNA samples (119 tumor/normal pairs). Briefly,
24 STR markers in regions showing loss of heterozygosity
in cancer were amplified using a touchdown PCR proto-
col. PCR amplification was carried out using 2.5 ng of
genomic DNA as template. The primers were each con-
jugated to one of the 3 fluorophores FAM, NED, or VIC
(Sigma-Aldrich, Applied Biosystems). PCR was performed
in 10 μL reactions containing 1 × PCR buffer (67 mM
Tris–HCl, pH 8.8, 6.7 mM MgCl2, 16.6 mM NH4SO4,
10 mM 2-mercaptoethanol), 1 mM dNTPs, 1 μM for-
ward and 1 μM reverse primers, 6% DMSO, 2 mM ATP,
0.25 U Platinum Taq (Invitrogen) and 2.5 ng DNA. Reac-
tions were carried out in 96-well ABI 2720 thermocyclers
using a touchdown PCR protocol (1 cycle of 96°C for
2 min; 3 cycles of 96°C for 10 sec, 64°C for 10 sec, 70°C
for 30 sec; 3 cycles of 96°C for 10 sec, 61°C for 10 sec,
70°C for 30 sec; 3 cycles of 96°C for10 sec, 58°C for
10 sec, 70°C for 30 sec; 41 cycles of 96°C for 10 sec, 57°C
for 10 sec, 70°C for 30 sec; 1 cycle of 70°C for 5 min).
Fluorescently labeled PCR products were analyzed by
fragment analysis in a capillary sequencing instrument
Figure 1 A workflow for serial extraction of DNA and RNA in tissue
biobanks. Tumor and patient-matched normal biopsies and surgical
specimens are embedded in OCT compound and frozen. Next, tissue
sections are sectioned and stained for inspection by a pathologist and
subsequent sections put in barcoded tubes in a tube rack for extraction.
When a full rack of specimens has been generated, DNA and RNA
molecules are serially extracted using the process presented in this work.
The resulting nucleic acid fractions are quantitated and packaged in tube
racks of sortable 96- or 384-well tubes for storage in automated freezers.
Figure 2 The extracted DNA is of high molecular weight and
integrity. Electrophoretic separation of genomic DNA from
colorectal and breast tissues on a 1% agarose gel.
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as size standard followed by allele identification using
GeneMapper Software v4.1 (Applied Biosystems).
Haloplex target enrichment for second-generation se-
quencing (Agilent) of 540 genes potentially implicated
in colorectal cancer was performed on 400–800 ng DNA
from 192 colorectal samples (96 tumor/normal pairs)
according to the manufacturer’s instructions [7]. The
enriched and barcoded targets were then deep sequenced
on an Illumina next generation sequencing platform
(Illumina) [8]. Sanger sequencing of the PCR products
amplified for mutation validation was carried out by an
initial touchdown PCR protocol as described above,
using the 192 samples previously deep sequenced on an
Illumina platform as DNA template. Following this, 18 μL
reactions were prepared containing 20 ng PCR product
template and 4 pmol M13 primer (Biomers). The se-
quence reactions were delineated at Uppsala Genome
Center on an ABI PRISM 3730xl sequencing apparatus
(Applied Biosystems).
Gene copy number analyses of 70 of the colon cancer
samples were performed using Genome Wide SNP6
microarrays (Affymetrix), according to the manufac-
turer’s instructions.
Results
Automated biomolecule extraction from tissues
The serial DNA/RNA extraction method described in [5]
was successfully implemented in a fully automated fashion
on a Tecan Freedom Evo workstation for parallel extrac-
tion of 96 samples or 1–96 samples using 8-channel liquid
handling. A tissue biobank workflow for integration
of the extraction process is outlined in Figure 1. By
omitting the grinding and shaking step of the original
procedure, the number of transfers and the amount
of hardware required in the robotic platform were reduced
while maintaining yields and biomolecule integrity (data
not shown). The total run time for extraction of 96 tissue
samples was 1 h 40 min or 3 h 20 min when DNA alone
or DNA and RNA, respectively, was recovered. The
dropout rate (no DNA in eluate) for the initial 576 sam-
ples was ~ 2%, and the dropouts were likely caused by
tissue clogging of the narrow bore fixed pipette tips.
The remaining 288 samples were extracted using a wider
bore 96 tip block (Tecan, art. no. 10290619), and there
were no sample dropouts in this set.
Serial recovery of high quality DNA and RNA from
tissue specimens
The mean DNA yield of all samples was 3.2 μg (SD = 0.08,
n = 576) as measured by a Nanodrop instrument and
0.9 μg (SD = 0.17) as measured by Qubit. The mean
260:280 ratio, used as a measure of protein contamination,
was 1.66. The median 260:230 ratio, used as a secondarymeasurement of purity and indicating the presence of salts
and other contaminants, was 1.57. The integrity of four
randomly selected DNA samples is shown in Figure 2,
where long strands of gDNA can be seen on a 1% agarose
gel stained with SYBR Safe. Yields and purity (assessed
Table 1 Yield and purity of DNA extracted from 552 colon and breast samples
Sample type Mean DNA yield (μg) Standard deviation Median OD 260:280 Median OD 260:230
Colon (n = 276) 3.15 0.14 1.73 1.72
Breast (n = 276) 3.25 0.87 1.49 1.09
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are presented in Table 1.Storage stability of extracted RNA
The integrity of eleven randomly chosen RNA samples were
measured using an RNA 6000 Pico assay. The RNA quality
was found to be acceptable for use in most downstream
processes, with an average RIN value across 11 samples of
6.85 at time zero. To assess storage stability, the samples
were stored at −70°C and assessed at 3 months (average
RIN = 6.69), 6 months (average RIN = 6.86) and 9 months
(average RIN = 6.45), demonstrating stability under these
conditions even with several freeze-thaw cycles. Peak pro-
files from each time point are shown in Figure 3. WeFigure 3 The extracted RNA maintains integrity upon storage. Electro
chip, illustrating the integrity of diluted RNA at four time points measured
zero (1:10), B. at 3 months (1:10), C. at 6 months (1:10) and D. at 9 monthshave previously demonstrated the successful use of
RNA from this extraction chemistry in RT-PCR [5].
Conventional and next-generation sequencing analyses
of genomic DNA
The extracted DNA was first used in PCR-based short
tandem repeat (STR) analysis to compare genomic loci
between tumor/normal matched samples to ensure that
they were correctly paired. This allowed the detection of
loss of heterozygosity in chromosomally unstable sam-
ples, as well as revealing that two of the paired samples
were mismatched (Additional file 2: Figure S2).
Next, 400 – 800 ng DNA (as measured by Qubit) from
96 pairs of matched tumor and normal colorectal tissue
(192 samples in total) was used in a Haloplex targetphoretic separation of RNA on a Bioanalyzer using an RNA 6000 Pico
every 3 months after initial extraction. A. represents integrity at time
(1:20).
Mathot et al. BMC Biotechnology 2013, 13:66 Page 5 of 6
http://www.biomedcentral.com/1472-6750/13/66enrichment and barcoding protocol (Agilent) and se-
quenced on an Illumina platform to identify driver mu-
tations and key pathways involved in colorectal cancer
(CrC) (Mathot et al., in progress). Plots of the fraction
of regions of interest covered by at least a certain read
depth, illustrating the quality of the data produced by
the NGS technology for both the normal and tumor
samples are shown in Figure 4. The mean read depth
was approximately 500 for the normal samples and
1000 for the tumor samples.
Identification of genomic aberrations using Genome Wide
SNP6 arrays (Affymetrix) was also carried out on 70 of the
CrC samples. The mean sample quality (QC) value as calcu-
lated by Nexus Copy Number™ software from Biodiscovery
(measuring the probe to probe variance) was 0.19 (SD =
0.05). A QC value in the range 0.15 - 0.20 is considered high
quality, with higher quality samples approaching 0.2.
Discussion and conclusions
Sample acquisition and preparation is becoming the most
time consuming step in large scale genomic analyses ofFigure 4 The extracted DNA is suitable for target enrichment and
sequencing by next generation technologies. A. Sequence coverage
of the median (solid line), first quartile (closely dotted line) and third
quartile (dotted line) tumor samples (n = 96), while B. Sequence
coverage of the median (solid line), first quartile (closely dotted line) and
third quartile (dotted line) normal samples (n = 96).solid tumors. We have therefore designed, implemented
and validated an automated method for the serial extrac-
tion of DNA and RNA molecules from tissues of various
types, with a particular view to using this method in
cancer genomic and transcriptomic studies. The auto-
mation solution proposed here enables a high-throughput,
cost-effective preparation of samples with minimal hands-
on time.
Tissue extraction presents a distinct set of problems
not applicable to blood or body fluids. Most extraction
methods, in particular with regard to RNA, require a ti-
tration of input material to determine the optimal input,
to avoid overloading the binding capacity [1]. Here we
describe a method that can extract uniformly from a
similar amount (approximately 25 mg each) of a variety
of input tissue types. The technique produces, on a large
scale, nucleic acids of high quality suitable for many
downstream processes. The process is suited to a wide
variety of tissue types, and has successfully been used to
extract more than ten different tumor and normal tis-
sues, including those of the liver, prostate, tonsil, colon,
breast, thymus, kidney, skin, uterus and lung (data not
shown). The extraction yield and purity is identical with
manual extraction using the same chemistry [5]. The
method presented here performs well when compared to
other established extraction techniques, despite the omis-
sion of extensive tissue homogenization steps. (Using a
standard phenol-chloroform extraction technique with an
overnight Proteinase K digestion on 25 mg of colon tissue
resulted in a DNA yield of 0.8 – 1.2 μg as measured on
the Nanodrop).
The quality of the extracted biomolecules was vali-
dated by several different methods, commonly employed
in cancer genetics. The extracted DNA was of high mo-
lecular weight with no apparent fragmentation, which is
essential in whole genome sequencing approaches. The
OD 260:280 ratio (measured by Nanodrop), frequently
used as an indication of protein contamination, was within
a range suitable for DNA analysis [9]. The OD 260:230
ratio (Nanodrop), used as a measure of the purity of DNA,
is slightly low, likely due to the absorbance of residual
guanidine at 230 nm [10]. This is inherent to methods
using chaotropic lysis buffers. However, the performance
of extracted DNA in any of the downstream applications
tested was not affected, even when using microarrays
known to be sensitive to low OD 260:230 ratios [11].
The concentration of double stranded DNA measured
by the fluorometric Qubit method, proved to be a more
useful measurement of amplifiable DNA, and compared
well with real time PCR amplification of LINE1 elements
(data not shown) [12]. The differences between Qubit
and Nanodrop measurements may be explained by the
fact that the Nanodrop instrument measures both single
and double stranded DNA, as well as single nucleotides,
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[10]. The performance and uniformity in next-generation
sequencing applications was validated by targeted enrich-
ment and sequencing of the exons of 540 genes in 192
tumor and normal colorectal tissue samples (Figure 4).
RIN values for RNA extracted from tissue can be variable
and depend greatly on the sectioning process and storage
conditions prior to extraction [13]. The extracted RNA
had RIN values near 7, which is suitable for many tech-
niques used to study RNA, e.g. cDNA generation by RT-
PCR and microarray analyses. In fact, values above 5.5 are
sufficient for most applications [13]. We noted during
development of the process that prior recovery of DNA
facilitates RNA recovery, thereby contributing to in-
creased quality of the RNA obtained [5].
Future developments include adapting the method to
extraction of nucleic acids from formalin-fixed, paraffin-
embedded (FFPE) tissues. In addition, in light of the
finding that sample mix up is a common problem in
cancer genetic studies (here illustrated by two
mismatched pairs out of 96), we have recognized the
need for robust and scalable identification methods. An
automatable genotyping method for possible incorpor-
ation to the process, targeting insertion and deletion
polymorphisms has also been developed [14]. Taken to-
gether, we have developed a walk-away automation solu-
tion to process fresh-frozen tissue specimens to high
quality biomolecules ready for use in cancer research
and diagnostics. This novel technology enables the sim-
ultaneous processing of many different types of tissue
samples in the pathology biobank workflow with a time
and cost reduction for the user.
Additional files
Additional file 1: Figure S1. The worktable layout on the Tecan Freedom
Evo robotic workstation.
Additional file 2: Figure S2. DNA extracted can be incorporated into
PCR-based downstream analysis. Capillary electrophoretograms from the
STR analysis of matched and unmatched tumor/normal pairs. A. shows a
matched tumor/normal pair, B. shows an unmatched tumor/normal pair.
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